Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.42 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGAV | P06756 | 1/20 | 0.40 |
| ▸ | CALCR | P30988 | 3/20 | 0.40 |
| ▸ | BACE1 | P56817 | 7/20 | 0.39 |
| ▸ | GRPR | P30550 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29805149 | 0.87 | CALCR (0.48) | CRHR1CRHR2CALCRBACE1GRPR | |
| SCHEMBL29805325 | 0.85 | BACE1 (0.44) | BACE1CTSD | |
| SCHEMBL29589213 | 0.84 | FNTA (0.42) | GRPR | |
| SCHEMBL31257073 | 0.84 | MAGI3 (0.44) | BACE1GRPRCTSD | |
| SCHEMBL31307253 | 0.83 | CRHR1 (0.49) | CRHR1CRHR2CALCRBACE1KEAP1 | |
| SCHEMBL29373353 | 0.83 | CRHR1 (0.42) | CRHR1CRHR2CALCRBACE1CTSD | |
| SCHEMBL31257072 | 0.82 | MAGI3 (0.48) | CRHR1CRHR2CALCRBACE1 | |
| SCHEMBL31257048 | 0.82 | CTSL (0.45) | ITGB3ITGAVGRPRKEAP1 | |
| SCHEMBL30390358 | 0.81 | CD274 (0.41) | PDCD1LG2CD274BACE1CTSD | |
| SCHEMBL31412207 | 0.81 | OPRD1 (0.46) | BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629409-B2 | Vaccine | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2026-05-19 | — | — | US | disclosed |
| US-20240226261-A9 | VACCINE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-07-11 | — | — | US | disclosed |
| US-20240148849-A1 | IMMUNOGENIC COMPOSITION, USE AND METHODS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-05-09 | — | — | US | disclosed |
| US-20240131136-A1 | VACCINE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-04-25 | — | — | US | disclosed |
| EP-4294433-A1 | IMMUNOGENIC COMPOSITION, USE AND METHODS | GlaxoSmithKline Biologicals SA (BE) | 2023-12-27 | — | — | EP | disclosed |
| US-11844828-B2 | Vaccine | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-12-19 | — | — | US | disclosed |
| US-20230248816-A9 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-08-10 | — | — | US | disclosed |
| US-20230066762-A1 | IMMUNOGENIC COMPOSITION | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-03-02 | — | — | US | disclosed |
| US-20220288190-A1 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-09-15 | — | — | US | disclosed |
| WO-2022175423-A1 | IMMUNOGENIC COMPOSITION, USE AND METHODS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-08-25 | — | — | WO | disclosed |
| US-20220221455-A1 | ANTIGEN BINDING PROTEINS AND ASSAYS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-07-14 | — | — | US | disclosed |
| CN-114667158-A | Immunogenic compositions | 葛兰素史克生物有限公司 | 2022-06-24 | — | — | CN | disclosed |
| EP-4009951-A1 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | GlaxoSmithKline Biologicals S.A. (BE) | 2022-06-15 | — | — | EP | disclosed |
| EP-4010014-A1 | IMMUNOGENIC COMPOSITION | GlaxoSmithKline Biologicals S.A. (BE) | 2022-06-15 | — | — | EP | disclosed |
| US-20220152182-A1 | VACCINE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-05-19 | — | — | US | disclosed |
| CN-114245746-A | Methods for preparing compositions comprising protein D polypeptides | 葛兰素史克生物有限公司 | 2022-03-25 | — | — | CN | disclosed |
| US-11266731-B2 | Vaccine | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-03-08 | — | — | US | disclosed |
| EP-3956666-A1 | ANTIGEN BINDING PROTEINS AND ASSAYS | GlaxoSmithKline Biologicals S.A. (BE) | 2022-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220288190-A1 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | CFD, PEPD, SERPINA6 | PDCD1LG2 1153/4885CD274 2578/4885CRHR1 1654/4885 |
| US-20230248816-A9 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | CFD, PEPD, SERPINA6 | PDCD1LG2 1153/4885CD274 2578/4885CRHR1 1654/4885 |
| US-12629409-B2 | Vaccine | MRPL21, STT3B, CD47 | PDCD1LG2 1212/4885CD274 932/4885CRHR1 4225/4885 |
| US-20230066762-A1 | IMMUNOGENIC COMPOSITION | CXCL10, CCL2, CCL11 | PDCD1LG2 1049/4885CD274 1027/4885CRHR1 1576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.